MPR Weekly Dose 105 - Antibody Therapies Restricted; Veklury Greenlit for Outpatients; Parsaclisib Indication Withdrawn; Pepaxto Withdrawal Reconsidered; Kimmtrak Approved

<p><span style="font-weight: 400;">Use of monoclonal antibodies restricted due to Omicron; Veklury given the go-ahead as an outpatient treatment; New data produces a reconsideration for Pepaxto withdrawal; And there's a new treatment approval for unresectable or metastatic uveal melanoma.</span></p>